[1]
|
Travis, W.D., Brambilla, E., Burke, A.P., et al. (2015) Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. Journal of Thoracic Oncology, 10, 1240-1242. https://doi.org/10.1097/JTO.0000000000000663
|
[2]
|
Gatta, G., Capocaccia, R., Botta, L., et al. (2017) Burden and Centralised Treatment in Europe of Rare Tumours: Results of RARECAREnet—A Population-Based Study. The Lancet Oncology, 18, 1022-1039. https://doi.org/10.1016/S1470-2045(17)30445-X
|
[3]
|
Qin, B., Jiao, X., Liu, K., et al. (2018) Clinical, Pathological and Treatment Factors Associated with the Survival of Patients with Primary Pulmonary Salivary Gland-Type Tumors. Lung Cancer, 126, 174-181. https://doi.org/10.1016/j.lungcan.2018.11.010
|
[4]
|
Jaramillo, S., Rojas, Y., Slater, B.J., et al. (2016) Childhood and Adolescent Tracheobronchial Mucoepidermoid Carcinoma (MEC): A Case-Series and Review of the Literature. Pediatric Surgery International, 32, 417-424. https://doi.org/10.1007/s00383-015-3849-y
|
[5]
|
Roden, A.C., García, J.J., Wehrs, R.N., et al. (2014) Histopathologic, Immunophenotypic and Cytogenetic Features of Pulmonary Mucoepidermoid Carcinoma. Modern Pathology, 27, 1479-1488. https://doi.org/10.1038/modpathol.2014.72
|
[6]
|
Song, Z., Liu, Z., Wang, J., et al. (2013) Primary Tracheobronchial Mucoepidermoid Carcinoma—A Retrospective Study of 32 Patients. World Journal of Surgical Oncology, 11, Article 62. https://doi.org/10.1186/1477-7819-11-62
|
[7]
|
Techavichit, P., Hicks, M.J., López-Terrada, D.H., et al. (2016) Mucoepidermoid Carcinoma in Children: A Single institutional Experience. Pediatric Blood & Cancer, 63, 27-31. https://doi.org/10.1002/pbc.25681
|
[8]
|
张谦, 曾骐, 陈诚豪, 等. 儿童气管黏液表皮样癌的外科治疗[J]. 中华小儿外科杂志. 2023, 44(5): 385-389.
|
[9]
|
Abele, M., Bajčiová, V., Wright, F., et al. (2022) Primary Lung Carcinoma in Children and Adolescents: An Analysis of the European Cooperative Study Group on Paediatric Rare Tumours (EXPeRT). European Journal of Cancer, 175, 19-30. https://doi.org/10.1016/j.ejca.2022.08.007
|
[10]
|
Jieli, Z., Yunzhi, Z., Nan, Z., et al. (2021) Different Effects of Bronchoscopic Interventions on Children and Adults with Tracheobronchial Mucoepidermoid Carcinoma. Tumori Journal, 108, 134-140. https://doi.org/10.1177/0300891621995898
|
[11]
|
Wang, H., Zhang, J., Li, D., et al. (2015) Efficacy of Bronchoscopic Therapies for Bronchial Mucoepidermoid Carcinoma in Children: Results from Six Patients. Tumori Journal, 101, 52-56. https://doi.org/10.5301/tj.5000213
|
[12]
|
Yu, Y., Song, Z., Chen, Z., et al. (2011) Chinese Pediatric and Adolescent Primary Tracheobronchial Tumors: A Hospital-Based Study. Pediatric Surgery International, 27, 721-726. https://doi.org/10.1007/s00383-011-2858-8
|
[13]
|
Han, S.W., Kim, H.P., Jeon, Y.K., et al. (2008) Mucoepidermoid Carcinoma of Lung: Potential Target of EGFR-Directed Treatment. Lung Cancer, 61, 30-34. https://doi.org/10.1016/j.lungcan.2007.11.014
|
[14]
|
Griffin, R. and Ramirez, R.A. (2017) Molecular Targets in Non-Small Cell Lung Cancer. Ochsner Journal, 17, 388-392.
|
[15]
|
Wu, Y., Han, L., Sheng, Y., et al. (2020) Cetuximab Monotherapy for Relapsing High-Grade Mucoepidermoid Carcinoma: A Case Report and Review of the Literature. Oral Oncology, 107, Article 104824. https://doi.org/10.1016/j.oraloncology.2020.104824
|
[16]
|
Milanovic, D., Jeremic, B., Kayser, G., et al. (2012) Relapsing High Grade Mucoepidermoid Carcinoma. Strahlentherapie und Onkologie, 188, 518-522. https://doi.org/10.1007/s00066-012-0096-1
|
[17]
|
Yamanaka, S., Suzuki, S., Ito, H., et al. (2023) Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens. International Journal of Molecular Sciences, 24, Article 1722. https://doi.org/10.3390/ijms24021722
|
[18]
|
Shinomiya, H., Ito, Y., Kubo, M., et al. (2016) Expression of Amphiregulin in Mucoepidermoid Carcinoma of the Major Salivary Glands: A Molecular and Clinicopathological Study. Human Pathology, 57, 37-44. https://doi.org/10.1016/j.humpath.2016.06.016
|
[19]
|
Seto, E. and Yoshida, M. (2014) Erasers of Histone Acetylation: The Histone Deacetylase Enzymes. Cold Spring Harbor Perspectives in Biology, 6, a18713. https://doi.org/10.1101/cshperspect.a018713
|
[20]
|
Ong, P.S., Wang, X.Q., Lin, H.S., et al. (2012) Synergistic Effects of Suberoylanilide Hydroxamic Acid Combined with Cisplatin Causing Cell Cycle Arrest Independent Apoptosis in Platinum-Resistant Ovarian Cancer Cells. International Journal of Oncology, 40, 1705-1713.
|
[21]
|
Almeida, L.O., Abrahao, A.C., Rosselli-Murai, L.K., et al. (2014) NFκB Mediates Cisplatin Resistance through Histone Modifications in Head and Neck Squamous Cell Carcinoma (HNSCC). FEBS Open Bio, 4, 96-104. https://doi.org/10.1016/j.fob.2013.12.003
|
[22]
|
Parag-Sharma, K., Tasoulas, J., Musicant, A.M., et al. (2021) Synergistic Efficacy of Combined EGFR and HDAC Inhibitors Overcomes Tolerance to EGFR Monotherapy in Salivary Mucoepidermoid Carcinoma. Oral Oncology, 115, Article 105166. https://doi.org/10.1016/j.oraloncology.2020.105166
|
[23]
|
Ferrara, N. (2002) VEGF and the Quest for Tumour Angiogenesis Factors. Nature Reviews Cancer, 2, 795-803. https://doi.org/10.1038/nrc909
|
[24]
|
Kerbel, R.S. (2008) Tumor Angiogenesis. The New England Journal of Medicine, 358, 2039-2049. https://doi.org/10.1056/NEJMra0706596
|
[25]
|
Mochizuki, D., Adams, A., Warner, K.A., et al. (2015) Anti-Tumor Effect of Inhibition of IL-6 Signaling in Mucoepidermoid Carcinoma. Oncotarget, 6, 22822-22835. https://doi.org/10.18632/oncotarget.4477
|
[26]
|
Ni, W., Chen, Z., Zhou, X., et al. (2021) Targeting Notch and EGFR Signaling in Human Mucoepidermoid Carcinoma. Signal Transduction and Targeted Therapy, 6, Article No. 27. https://doi.org/10.1038/s41392-020-00388-0
|
[27]
|
Keir, M.E., Butte, M.J., Freeman, G.J., et al. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. https://doi.org/10.1146/annurev.immunol.26.021607.090331
|
[28]
|
Aguilar, E.J., Ricciuti, B., Gainor, J.F., et al. (2019) Outcomes to First-Line Pembrolizumab in Patients with Non-Small-Cell Lung Cancer and Very High PD-L1 Expression. Annals of Oncology, 30, 1653-1659. https://doi.org/10.1093/annonc/mdz288
|
[29]
|
Incorvaia, L., Fanale, D., Badalamenti, G., et al. (2019) Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Advances in Therapy, 36, 2600-2617. https://doi.org/10.1007/s12325-019-01057-7
|
[30]
|
Li, H., Shyam, S.S., Jatwani, K., et al. (2024) Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma. Cancers, 16, Article 744. https://doi.org/10.3390/cancers16040744
|
[31]
|
Gyulai, M., Megyesfalvi, Z., Reiniger, L., et al. (2023) PD-1 and PD-L1 Expression in Rare Lung Tumors. Pathology and Oncology Research, 29, Article 1611164. https://doi.org/10.3389/pore.2023.1611164
|
[32]
|
Zhang, Y., Zhang, Z., Ding, Y., et al. (2021) Phase I Clinical Trial of EGFR-Specific CAR-T Cells Generated by the PiggyBac Transposon System in Advanced Relapsed/Refractory Non-Small Cell Lung Cancer Patients. Journal of Cancer Research and Clinical Oncology, 147, 3725-3734. https://doi.org/10.1007/s00432-021-03613-7
|
[33]
|
Feng, K., Guo, Y., Dai, H., et al. (2016) Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of Patients with EGFR-Expressing Advanced Relapsed/Refractory Non-Small Cell Lung Cancer. Science China Life Sciences, 59, 468-479. https://doi.org/10.1007/s11427-016-5023-8
|
[34]
|
Liu, M., Wang, X., Li, W., et al. (2020) Targeting PD-L1 in Non-Small Cell Lung Cancer Using CAR T Cells. Oncogenesis, 9, Article No. 72. https://doi.org/10.1038/s41389-020-00257-z
|